Delivery Order SPE2DE24D0013-SPE2D625F8UE6
- Not listed
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a delivery order valued at $2,471.70 by the Defense Department's Medical Supply Chain organization on July 18, 2025, with an ultimate completion date of August 1, 2025. This firm fixed-price delivery order carries no set-aside designation and represents procurement of diagnostic equipment, reagents, or testing services from Cepheid's core product portfolio, which includes GeneXpert...
- This delivery order, valued at $2,500, was awarded to Cepheid Inc. on July 23, 2025, by the Defense Logistics Agency's Medical Supply Chain division for completion by July 30, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation. Cepheid, a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, will deliver products or services under this order, which represents a relatively modest purchase within the company's broader federal...
- This delivery order, valued at $13.6K, was awarded on July 21, 2025, to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, by the Medical Supply Chain within the Department of Defense. The contract, which carries no set-aside designation and employs firm fixed-price terms, is scheduled for completion by July 28, 2025. Based on the contract nomenclature (XPCOV2/FLU/RSV-10), this delivery order pertains to diagnostic testing for COVID-19, influenza, and...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $2,410.20 to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions. This firm fixed-price delivery order, issued on July 21, 2025, with an ultimate completion date of July 28, 2025, carries no set-aside designation and represents a task order under Cepheid's broader contract vehicle with the federal government. The contract requires performance at Cepheid's...
- The U.S. Defense Logistics Agency, through its Medical Supply Chain division, awarded a delivery order valued at $20.4K to Cepheid Inc. on July 25, 2025, for molecular diagnostic solutions. Designated as Contract Number 4568895371 with the identifier XPCOV2/FLU/RSV-10, this firm fixed-price delivery order is set to be completed by August 1, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The contract involves diagnostics testing solutions, specifically targeting...
- The Defense Logistics Agency, through its Medical Supply Chain organization, awarded a delivery order valued at $1,277.84 to Cepheid Inc. (UEI: W6HQTMWB9Q28) on July 21, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at Cepheid's facility in Sunnyvale, California. The delivery order represents a continuation of Cepheid's established relationship with federal defense and healthcare agencies as...
- Cepheid, a molecular diagnostics manufacturer based in Sunnyvale, California, received a $6.8K delivery order from the Defense Logistics Agency's Medical Supply Chain division on July 22, 2025, for the KIT XPERT XPRESS COVID-19/FLU/RSV + Molecular Biology diagnostic kit. This firm fixed-price delivery order, with performance completion targeted for July 29, 2025, carries no set-aside designation and represents part of Cepheid's ongoing supply of molecular diagnostic testing solutions to...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, has been awarded a delivery order valued at $1,605.00 under contract GXMRSA-NXG-10, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order, which carries no set-aside designation, is funded by the Defense Medical Supply Chain, a defense-focused federal agency. The award represents Cepheid's continued provision of molecular diagnostic technologies and services to the...
- This delivery order, awarded on July 24, 2025, represents a $17,680 firm fixed-price contract between the Defense Logistics Agency's Medical Supply Chain division and Cepheid Inc. for a COVID-19/Influenza/RSV diagnostic kit containing 10 viral tests. The contract is set to be completed by July 31, 2025, with performance taking place at Cepheid's headquarters in Sunnyvale, California. This award is issued without a set-aside designation and falls under Cepheid's existing indefinite delivery...
- The U.S. Defense agency's Medical Supply Chain issued a delivery order valued at $4,901.39 to Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, under contract number GXCT/NG-10. This firm fixed-price delivery order, awarded on July 25, 2025, with an ultimate completion date of August 1, 2025, carries no set-aside designation. The work will be performed at Cepheid's facility in Sunnyvale, California. Cepheid specializes in providing advanced molecular...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F8UE6Delivery Order
This delivery order, valued at $1,840 and awarded to Cepheid Inc. on July 25, 2025, represents a firm fixed-price procurement under the Medical Supply Chain, a Defense agency funding source. The contract is set to be completed by August 1, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. As a leading manufacturer of molecular diagnostic solutions, Cepheid specializes in advanced diagnostic systems and test kits for infectious diseases and clinical testing, providing equipment and reagents to federal healthcare systems including the Department of Veterans Affairs, Indian Health Service, and Defense Logistics Agency. This award likely represents a delivery order issued under one of Cepheid's existing Indefinite Delivery Vehicle contracts, such as the Veterans Integrated Service Network 6 agreement valued at approximately $32.8 million or the VISN 21 contract valued at $2.5 million, both of which provide molecular diagnostic testing system reagents, assays, and PCR testing capabilities. The company's federal portfolio encompasses diagnostic solutions for COVID-19, influenza, respiratory syncytial virus, methicillin-resistant Staphylococcus aureus, and other infectious diseases, making this procurement consistent with Cepheid's established role as a trusted supplier of diagnostic technologies across the federal healthcare enterprise. No set-aside designation applies to this contract award.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 7/25/25 |